Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Aug 01, 2021 9:50pm
102 Views
Post# 33639040

RE:RE:AAIC presentation

RE:RE:AAIC presentationJust so you guys don't have heart palpitations wiating for the earth shattering news that you are expecting ..,here are the topics these two SCIENTISTS will be presenting to other SCIENTISTS...

ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: “Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.” Dr. Cashman will deliver this presentation and chair the Virtual Oral Session #55269 to be held on Thursday, July 29, from 1:00 PM – 2:15 PM MT.

Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: “Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.” The poster discusses conformational epitopes on misfolded proteins that represent unique targets for therapeutic antibodies. Dr. Kaplan will deliver her poster presentation in person in Denver and online. Please consult the AAIC website (https://alz.org/aaic/overview.asp) for venue, date and time of the presentation.

<< Previous
Bullboard Posts
Next >>